NECA attended NANETS (North American Neuroendocrine Tumor Society) Multidisciplinary Medical Symposium Las Vegas USA 5 – 7 November 2026. This was an opportunity to network and meet with with NET Multidisciplinary Team members from Canada, USA and Europe and discuss management of NETs. Importantly collaboration with Pharma was possible. INCA, represented by our CEO, presented the poster of SCAN survey results “The Role of NET Specialists in Diagnostics and Treatment – Comparison Global vs USA in 2019 – 2025”. During the meeting Meredith took part in a podcast discussing 20,30 and 40 year old patients diagnosed with NETs and the issues they face medically, physically and psychologically. A meeting was also set up for Patient Leaders which highlighted the work Patient Advocacy Groups have done in the past 12 months.
The Symposium reviewed:
- the classification of NETs based on gene expression & microenvironment, described emerging therapeutic targets and drug-engineering strategies being investigated in neuroendocrine neoplasms.
- described the efficacy and safety outcomes of retreatment with 177Lu-DOTATATE (rePRRT) in patients with well-differentiated neuroendocrine tumours, including progression-free survival, disease control rates, and treatment-related toxicities.
- described emerging therapeutic strategies under investigation for patients with high-grade and advanced neuroendocrine neoplasms. Evidence and new data shaping the management of early-stage and advanced extrapulmonary high-grade NEN.
- described the role of patient-reported outcomes and quality-of-life assessments in evaluating the impact of NENs and their treatment; and
- described basic concepts of artificial intelligence in medical imaging
Our own A/Prof David Chan did a presentation on Dual PET Imaging for NETS during the conference. We were also able to meet with leading NET Specialists to discuss and progress research projects.
ts.